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Double-blind Placebo-controlled Study With Interleukin-18
and Interleukin-12-encoding Plasmid DNA Shows
Antitumor Effect in Metastatic Melanoma in Gray Horses
Jessika-M.V. Mu¨ller,* Karsten Feige,* Patrizia Wunderlin,w Andreas Ho¨dl,z Marina L. Meli,y
Monika Seltenhammer,J Paula Grest,z Lesley Nicolson,# Claude Schelling,**
and Lucie M. Heinzerlingw w zz
Summary:Melanoma is a disease with high incidence in gray horses
and has limited therapeutic options in metastatic disease. Gene
therapy has shown some success in animal models and human
patients. A randomized double-blind, placebo-controlled study was
conducted to investigate 2 treatment options using cytokine-
encoding plasmid DNA in horses with metastatic melanoma to
induce immunologic antitumor eﬀects. Adult gray horses with
spontaneously occurring metastatic melanoma (n=26) were
included in the study. Treatment of 26 gray horses with metastatic
melanoma consisted of interleukin-18-encoding plasmid DNA,
interleukin-12-encoding plasmid DNA, or empty plasmid DNA
(control group), injected intratumorally, respectively. Tumor
response was assessed using ultrasound and caliper measurements
and histologic assessment of tumor biopsies. Signiﬁcant tumor
regression could be shown in both the treatment groups receiving
IL-18 and IL-12-encoding plasmid DNA whereas placebo-treated
control patients showed tumor growth over the course of the
treatment. In addition, 7 of 10 tumors from horses treated with
IL-18 or IL-12 showed peritumoral and/or intratumoral inﬂam-
matory inﬁltrates after treatment compared with 1 of the 6 in the
control group. The treatment as assessed by serial blood draws and
clinical investigation, was safe and well tolerated. These data
suggest that the intratumoral treatment with IL-18 and IL-12-
encoding plasmid DNA has antitumor eﬀects, which is well
tolerated and thus holds promise for the treatment of patients
with metastatic melanoma.
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(J Immunother 2011;34:58–64)
Melanoma is a tumor entity with an increasingincidence in humans and a high prevalence in gray
horses.1,2 Immunotherapeutic approaches present alterna-
tive strategies for the treatment of metastatic melanoma.3
Preclinical research has been hampered by the lack of a
natural animal model that is similar to human disease.
Features of the gray horse model include the occurrence of
disease in genetically predisposed individuals4 and sponta-
neous progression with metastases formation in other
organ systems.5 Spontaneous tumor regression has not
been reported. Primary tumors appear in the perianal
region, on the vulva, prepuce, and lips and are subsequently
metastasized to the skin, lymph nodes, parotid gland,
internal organs, and central nervous system.6 This is similar
to human melanoma progression. Interleukin-12 (IL-12)
and Interleukin-18 (IL-18) exert a variety of immune-
regulatory functions including production of interferon-g
(IFN-g), activation of cytotoxic T lymphocytes, and natural
killer cells,7–9 induction of apoptosis in tumor cells10 and
also antiangiogenic properties.11 In-vivo antitumor eﬀects
could be shown in clinical trials for recombinant IL-12 and
recombinant IL-18 protein while inducing moderate-
to-severe side eﬀects (IL-12:12,13; IL-18:14). IL-18-encoding
plasmid DNA has only been tested in mouse models and
showed antitumor eﬀects in B16 melanoma.15 IL-12-
encoding plasmid DNA treatment was shown to be safe
and eﬃcient for accessible melanoma metastases in an
earlier open-label study in melanoma patients.16 This is the
ﬁrst randomized double-blind, placebo-controlled study
to investigate the eﬃcacy of IL-18 and IL-12-encoding
plasmid DNA in naturally occurring metastatic melanoma.
Furthermore, safety and tolerability of therapy with
plasmid DNA coding for IL-18 or IL-12 was assessed.
MATERIALS AND METHODS
Transfection of Melanoma Cells With
pUSEr-IRES-IL-12 and pUSEr
Two diﬀerent equine melanoma cell lines (provided by
Dr M. Seltenhammer, Veterinary University of Vienna),
HoMelZh and HoMelW, were cultured at 371C and 5%
CO2 in RPMI 1640 media (Sigma Aldrich Chemie GmbH,
Buchs, Switzerland) with the addition of 10% fetal calf
serum (FCS, Bio Concept, Allschwil, Switzerland), and 1%Copyright r 2010 by Lippincott Williams & Wilkins
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of streptomycin/antifungal agent (Life Technologies AG,
Basel, Switzerland). Cell lines were transfected with IL-12-
encoding plasmid DNA (pUSEr-IRES-IL-12), with empty
plasmid (pUSEr) or left without transfection. Each test was
conducted in triplicate. For the transfection cell culture
medium OptiMEM I (Invitrogen, Basel, Switzerland) and
Lipofectamine 2000 (Invitrogen, Basel, Switzerland) were
used. The transfection procedure was carried out according
to the guidelines of the manufacturer. The cells were
incubated at 371C in a CO2 incubator for 26 hours. The cell
culture supernatant was harvested. To indirectly determine
the biological eﬃcacy of pUSEr-IRES-IL-12 in vitro,
equine peripheral blood lymphocytes (PBMC) were isolated
from horse blood and diluted to a concentration of 106/mL
medium (RPMI 1640, 10% fetal calf serum, 1% IL-2). They
were stimulated in cell culture in 24-well plates (0.5mL
cell suspension per well) with the supernatant from the
transfections or mock transfections (0.5mL per well)
described above. Phorbol myristate acetate (5 ng, PMA,
Sigma Aldrich Chemie GmbH, Buchs, Switzerland) and
ionomycine (500 ng, Sigma Aldrich Chemie GmbH, Buchs,
Switzerland) were used as positive controls. Cell lysis was
carried out after 24 hours stimulation with the supernatants
and 5 hours after the addition of PMA and ionomycine,
respectively. The RNA was isolated from the cell lysate
using a commercially available kit (RNeasy Mini Kit,
Qiagen AG, Basel, Switzerland). Subsequently, a quantita-
tive real-time RT-PCR analysis was done to identify the
content of messenger RNA coding for IFN-g as described
earlier.17 For relative quantiﬁcation equine GAPDH was
used as a housekeeping gene. To quantify the IFN-g RNA a
DDCT-calculation was used. Ampliﬁcation and relative
quantiﬁcation of RNA took place in an ABI Prism 7700
(TaqMan) sequence detection system (Applied Biosystems,
Foster City).
Study Design
The trial was a 3-armed, randomized, double-blind,
placebo-controlled study. The study protocol (No. 108/
2000) was approved by the Commission for Animal
Experiments of the Veterinary Department, Zurich. In-
formed consent was obtained from the animal owners. The
animals were randomized into 3 groups, 1 receiving IL-
12-encoding plasmid DNA, 1 receiving IL-18-encoding
plasmid DNA, and 1 receiving empty plasmid as control.
Treatment and assessment of tumors were made in a
double-blind manner. The study medication was packed in
neutral vials and after the end of the study the treatment
was unblinded.
In this study, 26 horses with metastatic melanoma
were included (IL-12-encoding plasmid DNA n=8, IL-18-
encoding plasmid DNA n=9, and control vector n=9).
Only horses with tumors with well-demarcated borders that
were easily accessible were included. The animals were
between 3 and 27 years of age (15.6±5.7 y) and included 12
geldings, 10 mares, and 4 stallions.
Treatment
Treatment consisted of IL-12-encoding plasmid DNA
(pUSEr-IRES-IL-12), IL-18-encoding plasmid DNA (pU-
SEr-IRES-IL-18), or control vector (pUSEr). Plasmid
DNA constructs for equine IL-12 and equine IL-18 and
empty plasmid were provided by Dr L. Nicolson (through
Intervet International, Boxmeer, The Netherlands) to the
Equine Clinic of the Vetsuisse Faculty, University of Zurich
in a lyophilized form. These constructs were produced and
characterized as described by Nicolson et al18 and
McMonagle et al.19 Eschericia coli bacteria were trans-
formed with the plasmids (Lipofectamine, Invitrogen AG,
Basel, Switzerland). For each construct 30-mg, the plasmid
DNA was puriﬁed using the EndoFree Plasmid Giga Kit
(QIAGEN AG, Basel, Switzerland) according to the
protocol of the manufacturer. The correct DNA size of
IL-12, IL-18, and the empty plasmid was examined by
agarose gel electrophoresis. The plasmid DNA thus
provided was diluted with sterile, pyrogen-free water (Aqua
ad injectabilia, Fresenius Kabi, Bad Homburg, Germany)
to a concentration of 500mg/mL and stored at 701C.
From this solution, single doses were aliquoted into
neutrally coded vials.
For intratumoral injection into metastases and assess-
ment of tumors, the horses were sedated according to
individual needs (0.5 to 1-mg/kg Xylazine intravenous (i.v.)
and 0.01 to 0.02mg/kg Butorphanole i.v. or 20 to 80mg/kg
Detomidine i.v. and Butorphanole). Approximately 250-mg
plasmid DNA in an aequeous solution was injected using
20-G hypodermic needles centrally into selected tumors on
days 1, 3, and 5 and again on days 15, 17, and 19.
Safety Assessment and Documentation
of Adverse Events
From day 1 to day 19, and on day 64, a clinical
examination was conducted with the assessment of heart
rate, rectal temperature, breathing rate, color and capillary
ﬁlling time of the mucosae, peristaltic function of intestines,
and general condition of the animals. The tumors were
assessed for local reactions such as swelling, hemorrhage, or
ulceration. On days 1, 5, 15, 19, and 64 complete blood
counts, clinical chemistry, and arterial blood gas analyses
were done. Blood chemistry included electrolytes (Na, K, Cl,
Ca, Mg, phosphate), bilirubin, glucose, urea, creatinine, total
protein, and enzymatic activity of the alcalic phosphatase
(AP), glutamate dehydrogenase (GLDH), aspartate amino-
transferase (AST), g-glutamyl transferase (g-GT), creatine
kinase (CK), sorbit dehydrogenase (SDH), and lactate
dehydrogenase (LDH). Blood gas analyses comprised blood
pH, partial pressures of CO2 and O2, concentration of
bicarbonate, base excess, and O2 saturation.
Assessment of Tumor Response
The tumors were assessed at baseline and on days 5,
15, 19, and 64 by measuring with calipers and also with
ultrasound. All the tumor sizes were documented. Mea-
surement by caliper was carried out measuring the largest
(a) and the perpendicular (b) diameter of each tumor.
Volumes were calculated with the formula a2b0.5. In
1 horse assessment by caliper was not possible owing to the
diﬃculty in palpation of the tumor (patient 8). Thus, 25
horses were assessed by calipers (IL-12: n=7; IL-18: n=9;
control plasmid: n=9). As this method was reliable, even
for large and convex tumors, this was the primary read-out
for tumor response. Sonographic assessment was done
using an 8.6 to 11MHz linear head (GE Logic 400, Pro
Series, GE Medical Systems AG, Glattbrugg, Switzerland).
In the B-mode the largest (a) and the perpendicular (b)
diameter were measured. Tumor volumes were calculated
with the formula a2b0.5.
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Histologic Analyses of the Biopsy Specimen
On day 1 (before the start of the treatment) a tumor
biopsy was taken. On day 64 (at the end of the treatment
cycle) a tumor biopsy of each treated tumor was conducted
or the tumor was completely removed. The injection site
was disinfected and anesthetized locally with lidocaine
(Lidocainhyaluronidase 2%, G. Streuli & Co. AG, Uznach,
Switzerland). According to tumor size, the specimens
were taken by using, either surgical instruments, single-
use punch biopsy instruments (Stiefel Laboratorium
GmbH, Oﬀenbach, Germany), or a Tru-cut needle biopsy
(Biopty, Radiplast AG, Uppsala, Sweden). The specimens
were ﬁxed in formalin (Formalin 4% buﬀered pH 7,
Kantonsapotheke Zurich, Switzerland) and embedded in
paraﬃn for histologic evaluation, cut at 4 mm and stained
with the hematoxylin-eosin stain (HE). In addition, the
sections that were prepared were bleached with H2O2 for 40
to 52 hours and stained with the HE stain. After the size of
the tumors had been measured, the biopsies were assessed
for ulcerations of the epidermis overlying the tumor,
junctional activity, growth type, and the presence of mitotic
ﬁgures in neoplastic cells. Inﬂammatory inﬁltrates, intratu-
morally or peritumorally, were registered separately and
categorized as minimal (±), mild (+), moderate (++),
or severe (+++) taking into account the extent (less than
1/3, between 1/3 and 1/2, more than 1/2) and the
distribution (focal, diﬀuse, perivascular). In addition, the
type of inﬂammatory cells (eg, lymphocytes, plasma cells,
neutrophils, eosinophils, or histiocytes) was recorded.
Moreover, the presence of necrotic areas or apoptotic cells
was evaluated. All histologic examinations were undertaken
blinded and by the same pathologist.
Pretreatment and posttreatment specimens were ana-
lyzed in 16 cases. In 7 cases only the follow-up biopsy was
examined and in 3 horses no biopsies were taken. A total of
40 biopsy specimens were examined.
Statistical Analyses
The statistical analyses were carried out with the
computer program Systat (Systat, 7.0 for Windows, SPSS,
Zurich, Switzerland). The average ( x±s) for normally
distributed values was indicated when assessing the results.
The comparison of the tumor volumes of the 3 diﬀerent
groups on day 1 was carried out with the help of an analysis
of variance (ANOVA). To calculate signiﬁcant diﬀerences
in tumor volumes within the group, an ANOVA for
repeated measurements was conducted. In the case of
signiﬁcant ANOVA, a paired t test was conducted to
compare the single values of each tumor with the respective
baseline value of that tumor. The association between the
sonographic tumor volume and the tumor volume mea-
sured by caliper was made using correlation analysis. The
results were considered signiﬁcant at a P-value of <0.05.
RESULTS
Transfection of Melanoma Cells With IL-12
Plasmid DNA and Empty Plasmid Vector
To determine whether the IL-12 construct was
functional, and as no enzyme linked immonosorbent
assays for the equine proteins are available, a transfection
experiment was conducted. The IL-18 construct had been
tested earlier.18 Expression of IFN-g in equine PBMC as
measured by RT-PCR could be stimulated using the
supernatant from the pUSEr-IRES-IL-12 transfected cells
of both equine melanoma cell lines whereas control
stimulations with Lipofectamine 2000 and Optimem I only,
did not induce production of IFN-g in the PBMCs.
The supernatant from melanoma cells transfected with the
empty plasmid vector pUSEr did not induce IFN-g in
the melanoma cell line, HoMelZH, whereas a slight
induction of IFN-g was observed in the other melanoma
cell line (HoMelW).
Injection of IL-12 and IL-18-encoding
Plasmid DNA Is Safe
A total of 26 horses with metastatic melanoma was
included in the study and randomized to treatment with
plasmid DNA coding for IL-12, IL-18, or with control
plasmid (Table 1). During the complete course of the study,
all 26 horses remained in good general condition. No
clinical adverse eﬀects were observed and no hematologic
toxicity or other laboratory abnormalities occurred. After
injection, the horses with small treated tumors (diameter
<1 cm) showed a peritumoral swelling that lasted from 1 to
3 days. This occurred in 5 of 9 animals injected with the
control vector, in 3 of 9 animals injected with IL-18-
encoding plasmid DNA, and in 4 of 8 animals injected with
IL-12-encoding plasmid DNA.
IL-18-encoding Plasmid DNA and IL-12-encoding
Plasmid DNA Induce Tumor Regression
A statistically signiﬁcant decrease in mean tumor
volume was noted in the IL-12 group between day 1 and
day 64 (P=0.017; paired t test; Fig. 1A). Tumor sizes in
the group treated with IL-18-encoding plasmid DNA
also decreased signiﬁcantly (Fig. 1B). A highly signiﬁcant
decrease in volume could be observed in group IL-18
between day 1 and day 15 (P=0.0001; paired t test) and
between day 1 and day 19 (P=0.012; paired t test). In the
control group no statistically signiﬁcant diﬀerence between
the tumor volumes occurred (Fig. 1C). Initially, there were
no diﬀerences between groups with respect to tumor sizes.
This was determined by ANOVA for the baseline values
of tumors as measured by calipers (P=0.202) and as
measured by ultrasound (P=0.357).
Similarly, the measurements by ultrasound showed a
pronounced decrease in tumor volumes in the course of the
treatment for the IL-18 group, and a slight decrease for the
IL-12 group while the control group showed no change
(data not shown). However, owing to the smaller sample
size for the ultrasound measurements (n=22) this did
not become statistically signiﬁcant. Sonographic tumor
volumes signiﬁcantly correlated with the tumor volumes
measured by caliper (P<0.0001; correlation coeﬃ-
cient=0.71 to 0.84).
Histologic Findings
In 7 of 10 tumors from horses of the treatment groups
(4 of 4 from the IL-12 group, 3 of 6 from the IL-18 group)
mild lymphocytic inﬁltrates were observed after treatment
on day 64 (example Fig. 2). Before therapy 2 of 11 tumors
had shown an inﬁltrate, 1 each in the IL-12 group and in
the IL-18 group (Table 2). In the control group, 1 of 6
tumors showed a minimal-to-mild perivascular lymphocytic
inﬁltrate before and after treatment, respectively (Table 2).
Two further specimens contained scattered lymphocytes
within the neoplastic tissue (1 treated with IL-18-encoding
plasmid DNA, 1 with IL-12-encoding plasmid DNA).
Necroses or thrombosed vessels were never observed.
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DISCUSSION
This double-blind, placebo-controlled study describes
the clinical eﬀects of an antitumor therapy with plasmid
DNA coding for IL-12 or IL-18 in naturally occurring
metastatic melanoma of gray horses by direct intratumoral
application of the DNA. Tumor regression was induced in
both treatment groups whereas the control group showed
tumor growth. Both therapy alternatives proved to be very
well tolerated with no signiﬁcant side eﬀects. In the IL-18
group tumor regression was already signiﬁcant on day 15
of the treatment cycle, for IL-12 regression was signiﬁcant
on day 64. These decreases of tumor volumes were
documented by 2 independent assessment methods (calipers
and ultrasound), which were carried out while the study
was still blinded. As cytokines have been shown to be
species-speciﬁc in some instances,20,21 this trial used DNA
coding for equine IL-12 and equine IL-18 (both sequenced
and cloned by Nicolson et al18) and transfection of
melanoma cells and expression of the gene products were
tested and bioactivity of transfected cell supernatant was
assessed.
For IL-12-encoding plasmid DNA, this is in accor-
dance with the earlier open trials in horses and human
patients.16,22 IL-18 with its antiangiogenic and antitumor
properties has been described as a candidate for tumor
therapy in mice.11,23,24 Recombinant murine IL-18 proved
to be eﬀective in CL8-110,25 and B16 melanoma26 even if the
mice were depleted of T cells and natural killer cells.27 Gray
horses that suﬀer from melanoma represent a good model
for research of melanoma therapy that is much closer to
human disease than syngeneic mouse models.22 This trial,
for the ﬁrst time, shows clinical activity of IL-18-encoding
plasmid DNA in naturally occurring metastatic melanoma.
This study used DNA coding for the cytokines IL-12
and IL-18 instead of recombinant interleukins. This
approach has been shown to have increased eﬃcacy and
decreased toxicity owing to the continuous local secretion
of IL-12 and IL-18, respectively.26–29 IL-12 plasmid DNA
was eﬀective in the treatment of established melanoma
in mice, naturally occurring equine melanoma, and in
human patients with metastatic melanoma.16,22,30 For IL-
18, murine gene transfer studies using adenoviruses,31,32
TABLE 1. Characteristics of the Patients
Tumor Volume
Day 0 Day 5 Day 15 Day 19 Day 64
Patient
ID
Treat-
ment
Sex
(M=Male;
F=Female)
Age
(years) Tumor Site mm3 mm3 mm3 mm3 mm3
% Baseline
Volume
14 IL-18 M 9 Face 40000.0 36000.0 33600.0 33462.0 24500.0 61
15 IL-18 M 12 Ventral tail 90.8 137.3 70.9 68.8 105.9 117
16 IL-18 F 13 Ventral tail, Perianal 847.0 1093.8 793.5 661.5 425.3 50
17 IL-18 M 3 Back, Limb 19602.0 22019.6 16279.4 19220.0 21424.5 109
18 IL-18 F 17 Back, Eye lid 3136.0 2812.5 2700.0 2401.0 2254.0 72
19 IL-18 M 10 Ventral tail, Perianal 968.0 1267.5 800.0 850.0 726.0 75
20 IL-18 M 9 Ventral tail, Perianal,
Penis, Prepuce
600.0 695.8 500.0 473.8 665.5 111
23 IL-18 F 22 Ventral tail, Perianal 397.4 281.3 352.0 211.3 384.8 97
25 IL-18 M* 24 Ventral tail, Perianal 253.1 309.4 253.1 281.8 267.2 106
8 IL-12 M 10 Ventral tail, Shoulder,
Limb
50744.3 50994.8 53463.5 58186.7 51942.9 102
9 IL-12 F 20 Ventral tail, Parotis 272.0 288.0 144.0 169.0 158.4 58
10 IL-12 M 19 Ventral tail, Perianal,
Penis, Prepuce
1047.4 950.0 1000.0 950.0 672.0 64
11 IL-12 F 14 Ventral tail, Perianal 220.5 239.1 169.0 162.0 169.0 77
12 IL-12 M 20 Ventral tail, Perianal,
Penis, Prepuce
2456.5 2916.0 5315.9 2112.0 2654.4 108
13 IL-12 M 12 Ventral tail, Perianal 550.0 288.0 405.0 445.5 405.0 74
21 IL-12 M* 27 Ventral tail, Perianal 744.6 825.0 1028.5 847.0 695.8 93
24 IL-12 F 16 Ventral tail, Parotis, Face 1813.0 2752.0 3034.5 1764.0 1436.5 79
1 Control M* 18 Ventral tail, Perianal,
Penis, Prepuce
281.3 158.4 323.4 323.4 158.8 56
2 Control M 16 Ventral tail, Perianal 760.4 525.0 665.5 606.4 473.8 62
3 Control M 24 Ventral tail, Perianal,
Penis, Prepuce
2475.0 2890.0 1913.6 2102.5 1892.3 76
4 Control F 19 Ventral tail, Perianal 75.0 171.5 147.9 158.4 117.0 156
5 Control F 18 Ventral tail, Perianal 2601.0 3429.5 1912.5 1800.0 1183.0 45
6 Control M 11 Ventral tail, Parotis 208.3 384.8 208.3 272.0 183.8 88
7 Control F 9 Ventral tail, Udder 295.3 245.0 288.0 288.0 364.5 123
22 Control F 12 Ventral tail, Perianal 68.8 50.6 117.0 158.4 105.9 154
26 Control M* 21 Ventral tail, Parotis,
Perianal
257.3 336.0 320.0 281.3 586.6 228
The diﬀerent treatment groups including age, sex, site of injection and tumor response, and course of tumor volumes (as measured by calipers). A total of 26
gray horses with metastatic melanoma was included for treatment with IL-12-encoding plasmid DNA (n=7), IL-18-encoding plasmid DNA (n=9), or control
plasmid (n=9).
*Stallion.
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retroviruses,33 electroporation,34 or application of plasmid
DNA35 showed potent antitumor eﬀects.
Furthermore, an activation of the immune system was
documented with inﬂammatory inﬁltrates in 7 of 10 treated
tumors from the IL-12 and IL-18 groups (3 in the IL-18
group and 4 in the IL-12 group) as compared with 1 of 6 in
the control group. This observation implies that IL-12 and
IL-18 both exert a positive eﬀect on the recruitment of
immune cells against tumors. In the study by Heinzerling et al,16
CD4 and CD8 lymphocytic inﬁltrates could be documented
in the IL-12-treated tumors and their periphery. The 2
cytokines, IL-12 and IL-18, act synergistically in terms of
immune stimulation. Tannenbaum et al36 showed that
chemokines, such as IP-10 and MIG, induced by the
administration of IL-12 and IL-18, respectively, increased
the chemotactic attraction of CD4 and CD8 lymphocytes.
These inﬁltrates in turn mediate the immunologic anti-
tumor eﬀect of the cytokines.37–39 In earlier studies, a
FIGURE 1. Changes of tumor volumes (mean ± SD) over the course of the treatment (day 1 to day 64) were measured using calipers
and are recorded for the groups treated with (A) IL-12-encoding plasmid DNA (n = 8), (B) IL-18-encoding plasmid DNA (n = 9), and (C)
control vector (n = 9). Plasmid DNA was injected on days 1, 3, and 5 and again on days 15, 17, and 19. Volumes are documented in
percent of baseline value. The tumor volume before the initial treatment corresponds to 100% (* indicates P < 0.05).
FIGURE 2. Histologic examination of posttreatment biopsies showing inflammatory infiltrates. A, Mild perivascular lymphocytic
infiltrates (arrows) in the border area of the melanoma, scale bar=20 mm. B, Mild-to-moderate perivascular lymphocytic infiltrates
(arrows) in the peritumoral tissue, scale bar=100mm. Slides were stained with hematoxylin-eosin.
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substantial inﬂux of macrophages into tumors after
treatment with IL-12 has been reported,36,40 which was
not observed in our study.
This study showed that intratumoral injection of IL-12
and IL-18-encoding plasmid DNA was safe and eﬀective
for the treatment of metastatic melanoma in a large animal
model. Both therapy alternatives induced signiﬁcant tumor
regression. A combination of these agents could be
considered for future studies.
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